Free Submission Public Relations &
Deutsch English


Dako enters collaboration with Eli Lilly and Company for development of companion diagnostics

Print article Print article
Copyright © Thomson Reuters 2013. All rights reserved.
2013-01-07 17:02:37 -

GLOSTRUP, Denmark, Jan. 7, 2013 - Dako, an Agilent Technologies company,
announced today it has entered into a master framework agreement with Eli Lilly
and Company for the development of companion diagnostic tests to identify
patients who may be more likely to benefit from an investigational oncology
medicine currently under development by Lilly.

The agreement constitutes a framework for collaboration between Dako and Lilly
with a focus on the Lilly oncology pipeline.

"Building lasting partnerships is a cornerstone to Dako," says Lars Holmkvist,
CEO of Dako and senior vice president, Agilent.  "I warmly welcome Lilly, and I
am excited about what we may accomplish together for the benefit of patients
worldwide. This agreement heralds our mutual commitment to fighting cancer."

Companion diagnostics are increasingly in demand with the recognition that
personalized medicine 
may provide a way to improve patient care and manage health-care costs by targeting treatments to individuals more likely to benefit from specific therapies. "Tailored therapies are a key component of Lilly's strategy of providing improved outcomes for individual patients," says Greg Zdechlik, chief operating officer, Diagnostics, Eli Lilly and Company. "We look forward to collaborating with Dako in an effort to develop oncology companion diagnostics for patients worldwide who are waiting." Dako has a strong heritage of developing diagnostic tests in collaboration with pharmaceutical companies. The collaboration with Lilly is another example of Dako's position in the clinical diagnostics market as a strong partner for developing diagnostic tests for use in conjunction with medicines. About Dako - An Agilent Technologies Company Dako, based in Denmark, is a global leader in tissue-based cancer diagnostics. Hospital and research laboratories worldwide use Dako's reagents, instruments, software and expertise to make accurate diagnoses and determine the most effective treatment for cancer patients. Dako, with 1,200 employees, operates in more than 100 countries. Dako became part of Agilent Technologies on June 21, 2012. Information about Dako is available at About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company's 20,500 employees serve customers in more than 100 countries. Agilent had revenues of $6.9 billion in fiscal 2012. Information about Agilent is available at EDITORIAL CONTACT: Maia Fredtoft Søchting, Dako +45 25 46 10 83 This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Dako Denmark A/S via Thomson Reuters ONE [HUG#1668620]

Press Information:

Contact Person:

Disclaimer: © 2014 Thomson Reuters. The press releases or report contained herein is protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Thomson Reuters's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News


Terms & Conditions | Privacy | About us | Contact